An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread

Local Institution - 0029, Sydney

Local Institution - 0046, Westmead

Local Institution - 0045, North Sydney

Local Institution - 0004, Melbourne

Local Institution - 0008, Clayton

Local Institution - 0044, Brisbane

Local Institution - 0047, Nedlands

Local Institution - 0041, New York

Local Institution - 0053, Marseille

Local Institution - 0057, Pittsburgh

Local Institution - 0009, Rozzano MI

Local Institution - 0010, Milan

Local Institution - 0011, Milan

Local Institution - 0012, Milan

Local Institution - 0051, Lutherville

Local Institution - 0016, Madrid

Local Institution - 0018, Madrid

Local Institution - 0005, Atlanta

Local Institution - 0048, Atlanta

Local Institution - 0023, Toulouse

Local Institution - 0043, Nashville

Local Institution - 0052, Nantes

Local Institution - 0030, Cleveland

Local Institution - 0019, Essen

Local Institution - 0049, Detroit

Local Institution - 0040, Lille

Local Institution - 0027, Chicago

Local Institution - 0006, St Louis

Local Institution - 0024, Lyon

Local Institution - 0013, Heilbronn

Local Institution - 0025, Paris

Local Institution - 0022, Villejuif

Local Institution - 0028, Tucson

Local Institution - 0026, La Jolla

Local Institution - 0035, Tampa

Local Institution - 0033, Hackensack

Local Institution - 0034, Philadelphia

Local Institution - 0003, Edmonton

Local Institution - 0002, Vancouver

Local Institution - 0001, Toronto

Local Institution, Greenfield Park

Local Institution - 0036, Montreal

Local Institution - 0059, Helsinki

Local Institution - 0054, Oslo

Local Institution - 0042, Warsaw

Local Institution - 0017, Barcelona

Local Institution - 0055, Solna